ArticleSchizophrenia bulletin2016
Levels of Red Blood Cell Fatty Acids in Patients With Psychosis, Their Unaffected Siblings, and Healthy Controls.
Article in Schizophrenia bulletin, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 37 citations in OpenAlex.
- Longitudinal investigation of the relationship between omega-3 polyunsaturated fatty acids and neuropsychological functioning in recent-onset psychosis: A randomized clinical trial.Schizophrenia research · 2021Trial
- Omega-3 fatty acids in mental disorders: from neurobiological and metabolic mechanisms to therapeutic potential.Frontiers in nutrition · 2026Review
- Erythrocyte membrane nervonic acid in drug-naive first-episode psychosis and chronic medicated schizophrenia: Implication for impaired myelination and prognosis.World journal of psychiatry · 2025Article
- Article
- Revealing genetic causality between blood-based biomarkers and major depression in east Asian ancestry.Frontiers in psychiatry · 2024Article
- Relationships between erythrocyte membrane mono- and poly- unsaturated fatty acid composition and clinical/cognitive indices in antipsychotic-free schizophrenia patients.Frontiers in psychiatry · 2024Article
- DHA Shortage Causes the Early Degeneration of Photoreceptors and RPE in Mice With Peroxisomal β-Oxidation Deficiency.Investigative ophthalmology & visual science · 2023Article
- The shared genetic landscape of blood cell traits and risk of neurological and psychiatric disorders.Cell genomics · 2023Article
- Analysis of polyunsaturated fatty acids in antipsychotic-free individuals with at-risk mental state and patients with first-episode schizophrenia.Frontiers in psychiatry · 2023Article
- Higher stress response and altered quality of life in schizophrenia patients with low membrane levels of docosahexaenoic acid.Frontiers in psychiatry · 2023Article
- Disrupted leptin-fatty acid biosynthesis is an early manifestation of metabolic abnormalities in schizophrenia.World journal of psychiatry · 2022Article
- Peroxisomal Multifunctional Protein 2 Deficiency Perturbs Lipid Homeostasis in the Retina and Causes Visual Dysfunction in Mice.Frontiers in cell and developmental biology · 2021Article
- Omega-3 and Omega-6 fatty acids and risk of psychotic outcomes in the ALSPAC birth cohort.Schizophrenia research · 2020Article
- Beneficial effects of omega-3 fatty acid supplementation in schizophrenia: possible mechanisms.Lipids in health and disease · 2020Review
- Relationship Between Polyunsaturated Fatty Acids and Psychopathology in the NEURAPRO Clinical Trial.Frontiers in psychiatry · 2019Article
- Docosahexaenoic acid (DHA): An essential nutrient and a nutraceutical for brain health and diseases.Prostaglandins, leukotrienes, and essential fatty acids · 2018Review
- Focus on fatty acids in the neurometabolic pathophysiology of psychiatric disorders.Journal of inherited metabolic disease · 2018Review
- The novel antibiotic rhodomyrtone traps membrane proteins in vesicles with increased fluidity.PLoS pathogens · 2018Article
- Psychosis as an Evolutionary Adaptive Mechanism to Changing Environments.Frontiers in psychiatry · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTwo recent meta-analyses showed decreased red blood cell (RBC) polyunsaturated fatty acids (FA) in schizophrenia and related disorders. However, both these meta-analyses report considerable heterogeneity, probably related to differences in patient samples between studies. Here, we investigated whether variations in RBC FA are associated with psychosis, and thus may be an intermediate phenotype of the disorder.
methodsFor the present study, a total of 215 patients (87% outpatients), 187 siblings, and 98 controls were investigated for multiple FA analyses. Based on previous studies, we investigated docosahexaenoic acid (DHA), docosapentaenoic acid (DPA), arachidonic acid (AA), linoleic acid (LA), nervonic acid (NA), and eicasopentaenoic acid (EPA). On an exploratory basis, a large number of additional FA were investigated. Multilevel mixed models were used to compare the FA between the 3 groups.
resultsCompared to controls, both patients and siblings showed significantly increased DHA, DPA, AA, and NA. LA was significantly higher in siblings compared to controls. EPA was not significantly different between the 3 groups. Also the exploratory FA were increased in patients and siblings.
conclusionsWe found increased RBC FA DHA, DPA, AA, and NA in patients and siblings compared to controls. The direction of change is similar in both patients and siblings, which may suggest a shared environment and/or an intermediate phenotype. Differences between patient samples reflecting stage of disorder, dietary patterns, medication use, and drug abuse are possible modifiers of FA, contributing to the heterogeneity in findings concerning FA in schizophrenia patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.